• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Am J Pathol . Administration of a CXCR2 antagonist, SCH527123, together with oseltamivir suppresses NETosis and protects mice from lethal influenza

tetano

Editor, Senior Moderator
Am J Pathol


. 2021 Jan 13;S0002-9440(21)00002-X.
doi: 10.1016/j.ajpath.2020.12.013. Online ahead of print.
Administration of a CXCR2 antagonist, SCH527123, together with oseltamivir suppresses NETosis and protects mice from lethal influenza and piglets from swine-influenza infection


Harshini K Ashar[SUP] 1 [/SUP], Sivasami Pulavendran[SUP] 1 [/SUP], Jennifer M Rudd[SUP] 1 [/SUP], Prasanthi Maram[SUP] 1 [/SUP], Mallika Achanta[SUP] 1 [/SUP], Vincent Tk Chow[SUP] 2 [/SUP], Jerry R Malayer[SUP] 1 [/SUP], Timothy A Snider[SUP] 1 [/SUP], Narasaraju Teluguakula[SUP] 3 [/SUP]



Affiliations

Abstract

Excessive neutrophil influx, their released neutrophil extracellular traps (NETs) and extracellular histones are associated with disease severity in influenza-infected patients. Neutrophil chemokine receptor CXCR2 is a critical target for suppressing neutrophilic inflammation. Here, we investigated temporal dynamics of neutrophil activity and NETosis to determine the optimal timing of treatment with the CXCR2 antagonist, SCH527123 and we tested its efficacy together with antiviral agent, oseltamivir in murine and piglet influenza-pneumonia models. Our studies revealed that SCH527123 plus oseltamivir markedly improved survival of mice infected with lethal-influenza, and diminished lung pathology in swine-influenza-infected piglets. Mechanistically, addition of SCH527123 in the combination treatment attenuated neutrophil influx, NETosis in both mice and piglets. Further, neutrophils isolated from influenza-infected mice showed greater susceptibility to NETotic death when stimulated with a CXCR2 ligand, IL-8. In addition, CXCR2-stimulation induced nuclear translocation of neutrophil elastase, and enhanced citrullination of histones that triggers chromatin decondensation during NETs formation. Studies on temporal dynamics of neutrophils and NETs during influenza thus provide important insights into the optimal timing of CXCR2 antagonist treatment for attenuating neutrophil-mediated lung pathology. These findings reveal that pharmacological treatment with CXCR2 antagonist plus antiviral agent could significantly ameliorate morbidity and mortality in virulent and sub-lethal influenza infections.
 
Back
Top Bottom